| Title |
Review of photodynamic therapy in actinic keratosis and basal cell carcinoma
|
|---|---|
| Published in |
Therapeutics and Clinical Risk Management, February 2008
|
| DOI | 10.2147/tcrm.s1769 |
| Pubmed ID | |
| Authors |
Marica B Ericson, Ann-Marie Wennberg, Olle Larkö |
| Abstract |
The number of non-melanoma skin cancers is increasing worldwide, and so also the demand for effective treatment modalities. Topical photodynamic therapy (PDT) using aminolaevulinic acid or its methyl ester has recently become good treatment options for actinic keratosis and basal cell carcinoma; especielly when treating large areas and areas with field cancerization. The cure rates are usually good, and the cosmetic outcomes excellent. The only major side effect reported is the pain experienced by the patients during treatment. This review covers the fundamental aspects of topical PDT and its application for treatment of actinic keratosis and basal cell carcinoma. Both potentials and limitations will be reviewed, as well as some recent development within the field. |
Mendeley readers
The data shown below were compiled from readership statistics for 134 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 1 | <1% |
| Ireland | 1 | <1% |
| South Africa | 1 | <1% |
| Unknown | 131 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 24 | 18% |
| Student > Master | 24 | 18% |
| Student > Doctoral Student | 14 | 10% |
| Student > Bachelor | 14 | 10% |
| Researcher | 14 | 10% |
| Other | 20 | 15% |
| Unknown | 24 | 18% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 31 | 23% |
| Chemistry | 19 | 14% |
| Agricultural and Biological Sciences | 14 | 10% |
| Physics and Astronomy | 13 | 10% |
| Biochemistry, Genetics and Molecular Biology | 10 | 7% |
| Other | 17 | 13% |
| Unknown | 30 | 22% |
Attention Score in Context
This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 18 September 2012.
All research outputs
#7,355,930
of 25,373,627 outputs
Outputs from Therapeutics and Clinical Risk Management
#379
of 1,323 outputs
Outputs of similar age
#39,532
of 172,948 outputs
Outputs of similar age from Therapeutics and Clinical Risk Management
#14
of 21 outputs
Altmetric has tracked 25,373,627 research outputs across all sources so far. This one has received more attention than most of these and is in the 69th percentile.
So far Altmetric has tracked 1,323 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 9.6. This one has gotten more attention than average, scoring higher than 69% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 172,948 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 74% of its contemporaries.
We're also able to compare this research output to 21 others from the same source and published within six weeks on either side of this one. This one is in the 28th percentile – i.e., 28% of its contemporaries scored the same or lower than it.